When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

BioNTech (NasdaqGS:BNTX) recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming ...

Scientists project that by 2026 the results of clinical trials being conducted in 25 countries, including Spain, will be ...

A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

The Trump administration's unprecedented $500 million grant for a broadly protective flu shot has confounded vaccine and ...

The Trump administration last week canceled the first bargaining session scheduled with the U.S. Food and Drug Administration ...

A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.

(Reuters) -Difficult economic conditions and persistently weak demand for many products have forced companies across Europe ...

Research teams across Canada are now building mRNA to expand the potential of RNA vaccines beyond infectious diseases.